Insider Trading Alert - DXPE, CMI And MNTA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 19, 2014, 147 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $80.88 to $19,640,406.96.

Highlighted Stocks Traded by Insiders:

DXP (DXPE) - FREE Research Report

Vinson David C, who is Sr. V.P. at DXP, bought 2,000 shares at $65.21 on May 19, 2014. Following this transaction, the Sr. V.P. owned 15,432 shares meaning that the stake was reduced by 14.89% with the 2,000-share transaction.

Wick Stephen Norbert, who is VP Controller at DXP, bought 500 shares at $65.78 on May 19, 2014. Following this transaction, the VP Controller owned 1,042 shares meaning that the stake was reduced by 92.25% with the 500-share transaction.

Jeffery John Jay, who is Svp at DXP, bought 1,100 shares at $66.43 on May 19, 2014. Following this transaction, the Svp owned 11,665 shares meaning that the stake was reduced by 10.41% with the 1,100-share transaction.

Hamlin Todd, who is Sr. Vice President at DXP, bought 300 shares at $65.58 on May 19, 2014. Following this transaction, the Sr. Vice President owned 18,633 shares meaning that the stake was reduced by 1.64% with the 300-share transaction.

Yee Kent Nee Hung, who is Sr. Vice President at DXP, bought 150 shares at $64.79 on May 19, 2014. Following this transaction, the Sr. Vice President owned 18,136 shares meaning that the stake was reduced by 0.83% with the 150-share transaction.

Crane Wayne, who is Sr Vp Cio at DXP, bought 1,000 shares at $65.04 on May 19, 2014. Following this transaction, the Sr Vp Cio owned 3,000 shares meaning that the stake was reduced by 50% with the 1,000-share transaction.

The shares most recently traded at $66.24, up $1.20, or 1.81% since the insider transaction. Historical insider transactions for DXP go as follows:

  • 4-Week # shares sold: 11,979
  • 12-Week # shares sold: 11,979
  • 24-Week # shares bought: 600
  • 24-Week # shares sold: 103,391

The average volume for DXP has been 160,700 shares per day over the past 30 days. DXP has a market cap of $968.2 million and is part of the services sector and wholesale industry. Shares are down 43.13% year-to-date as of the close of trading on Monday.

DXP Enterprises, Inc. is engaged in distributing maintenance, repair, and operating (MRO) products, equipment, and services to industrial customers in the United States. It operates through three segments: Service Centers, Supply Chain Services, and Innovative Pumping Solutions. The company has a P/E ratio of 17.4. Currently, there are no analysts who rate DXP a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on DXPE - FREE

TheStreet Quant Ratings rates DXP as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full DXP Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cummins (CMI) - FREE Research Report

Herman Alexis M, who is Director at Cummins, sold 2,908 shares at $151.50 on May 19, 2014. Following this transaction, the Director owned 27,338 shares meaning that the stake was reduced by 9.61% with the 2,908-share transaction.

Carter Pamela L, who is President-Distribution at Cummins, sold 4,578 shares at $150.68 on May 19, 2014. Following this transaction, the President-Distribution owned 12,922 shares meaning that the stake was reduced by 26.16% with the 4,578-share transaction.

The shares most recently traded at $148.83, down $1.85, or 1.25% since the insider transaction. Historical insider transactions for Cummins go as follows:

  • 4-Week # shares sold: 26,397
  • 12-Week # shares sold: 26,397
  • 24-Week # shares sold: 51,824

The average volume for Cummins has been 1.4 million shares per day over the past 30 days. Cummins has a market cap of $27.5 billion and is part of the industrial goods sector and industrial industry. Shares are up 6.48% year-to-date as of the close of trading on Monday.

Cummins Inc. designs, manufactures, distributes, and services diesel and natural gas engines, and engine-related component products. It operates in four segments: Engine, Components, Power Generation, and Distribution. The stock currently has a dividend yield of 1.67%. The company has a P/E ratio of 18.1. Currently, there are 11 analysts who rate Cummins a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CMI - FREE

TheStreet Quant Ratings rates Cummins as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, increase in net income and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Cummins Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Momenta Pharmaceuticals (MNTA) - FREE Research Report

Shea Richard P, who is Svp, Cfo at Momenta Pharmaceuticals, sold 146 shares at $11.09 on May 19, 2014. Following this transaction, the Svp, Cfo owned 179,301 shares meaning that the stake was reduced by 0.08% with the 146-share transaction.

The shares most recently traded at $11.85, up $0.76, or 6.41% since the insider transaction. Historical insider transactions for Momenta Pharmaceuticals go as follows:

  • 4-Week # shares sold: 485
  • 12-Week # shares sold: 3,933
  • 24-Week # shares sold: 74,683

The average volume for Momenta Pharmaceuticals has been 995,500 shares per day over the past 30 days. Momenta Pharmaceuticals has a market cap of $630.3 million and is part of the health care sector and drugs industry. Shares are down 31.62% year-to-date as of the close of trading on Monday.

Momenta Pharmaceuticals, Inc., a biotechnology company, is engaged in the structural characterization, process engineering, and biologic systems analysis of complex molecules in the areas of complex generics, biosimilars, and novel drugs. Currently, there are 3 analysts who rate Momenta Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNTA - FREE

TheStreet Quant Ratings rates Momenta Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Momenta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers